Immobilization-assisted abdominal deep inspiration breath-hold in post-mastectomy radiotherapy of left-sided breast cancer with internal mammary chain coverage. 2021

Meiqin Chen, and Shoumei Zang, and Hao Yu, and Lihua Ning, and Huijie Huang, and Luyi Bu, and Jia Ge, and Mengyou Xu, and Qiuying Tang, and Feng Zhao, and Guorong Yao, and Senxiang Yan
Department of Radiation Oncology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou and Department of Radiation Oncology, Affiliated Jinhua Hospital, College of Medicine, Zhejiang University, Jinhua, China.

BACKGROUND Whether to prophylactically irradiate the ipsilateral internal mammary chain (IMC) in post-mastectomy radiotherapy (PMRT) remains controversial because of equivocal clinical benefits against the added toxicities. Our previous study revealed that the cardiac dose was decreased during left-sided breast radiotherapy with abdominal deep inspiration breath-hold (aDIBH) as compared with free-breathing (FB) and thoracic deep inspiration breath-hold (tDIBH). Here we present the dosimetric advantage of aDIBH for patients undergoing PMRT with IMC coverage. METHODS We prospectively analyzed 19 patients with left-sided breast cancer who underwent PMRT. Patients underwent computed tomography (CT) simulation under both free-breathing (FB) and aDIBH. The heart, left anterior descending coronary artery (LAD), lungs, and the contralateral breast was defined as organs at risk (OARs). Three-dimensional conformal radiation therapy (3D-CRT), inverse planning intensity-modulated radiation therapy (IMRT), and volumetric modulated arc therapy (VMAT) were used to calculate the doses received by both the planning target volume (PTV) and OARs, which were compared using the Wilcoxon signed-rank test. RESULTS Compared with FB, the Dmean of the heart and LAD were respectively reduced by 3.5 Gy (P<0.003) and 8.9 Gy (P<0.001) in 3D-CRT, 2.6 Gy (P<0.001), and 7.8 Gy (P=0.001) in IMRT, 1.5 Gy (P<0.001) and 4.5 Gy (P=0.001) in VMAT plans under aDIBH. Among all these plans, the Dmean of the heart was lowest in aDIBH IMRT and 1.3 Gy lower than in aDIBH VMAT (P=0.002). aDIBH IMRT also resulted in a significantly reduced dose to the ipsilateral lung than plans under FB (P<0.05). Dmean and V5 to the contralateral lung and breast were higher in VMAT plans (P<0.05). CONCLUSIONS Using an immobilization-assisted aDIBH technique, radiation doses to the heart can be kept at reasonably low levels even if IMC is included in the clinical target volume (CTV). Among 3D-CRT, IMRT, and VMAT plans, IMRT plus aDIBH results in the best heart-sparing effect. We recommend that the aDIBH technique be routinely applied in suitable patients if the IMC is irradiated.

UI MeSH Term Description Entries

Related Publications

Meiqin Chen, and Shoumei Zang, and Hao Yu, and Lihua Ning, and Huijie Huang, and Luyi Bu, and Jia Ge, and Mengyou Xu, and Qiuying Tang, and Feng Zhao, and Guorong Yao, and Senxiang Yan
May 2018, Radiation oncology (London, England),
Meiqin Chen, and Shoumei Zang, and Hao Yu, and Lihua Ning, and Huijie Huang, and Luyi Bu, and Jia Ge, and Mengyou Xu, and Qiuying Tang, and Feng Zhao, and Guorong Yao, and Senxiang Yan
January 2021, Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti,
Meiqin Chen, and Shoumei Zang, and Hao Yu, and Lihua Ning, and Huijie Huang, and Luyi Bu, and Jia Ge, and Mengyou Xu, and Qiuying Tang, and Feng Zhao, and Guorong Yao, and Senxiang Yan
January 2015, Medical physics,
Meiqin Chen, and Shoumei Zang, and Hao Yu, and Lihua Ning, and Huijie Huang, and Luyi Bu, and Jia Ge, and Mengyou Xu, and Qiuying Tang, and Feng Zhao, and Guorong Yao, and Senxiang Yan
August 2012, Journal of medical imaging and radiation oncology,
Meiqin Chen, and Shoumei Zang, and Hao Yu, and Lihua Ning, and Huijie Huang, and Luyi Bu, and Jia Ge, and Mengyou Xu, and Qiuying Tang, and Feng Zhao, and Guorong Yao, and Senxiang Yan
January 2022, Journal of X-ray science and technology,
Meiqin Chen, and Shoumei Zang, and Hao Yu, and Lihua Ning, and Huijie Huang, and Luyi Bu, and Jia Ge, and Mengyou Xu, and Qiuying Tang, and Feng Zhao, and Guorong Yao, and Senxiang Yan
January 2017, Tumori,
Meiqin Chen, and Shoumei Zang, and Hao Yu, and Lihua Ning, and Huijie Huang, and Luyi Bu, and Jia Ge, and Mengyou Xu, and Qiuying Tang, and Feng Zhao, and Guorong Yao, and Senxiang Yan
January 2022, Frontiers in oncology,
Meiqin Chen, and Shoumei Zang, and Hao Yu, and Lihua Ning, and Huijie Huang, and Luyi Bu, and Jia Ge, and Mengyou Xu, and Qiuying Tang, and Feng Zhao, and Guorong Yao, and Senxiang Yan
January 2023, Frontiers in oncology,
Meiqin Chen, and Shoumei Zang, and Hao Yu, and Lihua Ning, and Huijie Huang, and Luyi Bu, and Jia Ge, and Mengyou Xu, and Qiuying Tang, and Feng Zhao, and Guorong Yao, and Senxiang Yan
June 2017, Acta oncologica (Stockholm, Sweden),
Meiqin Chen, and Shoumei Zang, and Hao Yu, and Lihua Ning, and Huijie Huang, and Luyi Bu, and Jia Ge, and Mengyou Xu, and Qiuying Tang, and Feng Zhao, and Guorong Yao, and Senxiang Yan
August 2021, Clinical breast cancer,
Copied contents to your clipboard!